Emcure Pharmaceuticals Limited — Investor Meet, 11-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** Emcure Pharmaceuticals reported Q3 revenue of INR 1,963 crore, an 18% increase year-on-year. Adjusted PAT grew by 43% to INR 171 crore, while reported PAT stood at INR 156 crore. The gross margin decreased to 60.1%, down from 62.7% in the previous year due to a shift in business mix. EBITDA increased by 23% to INR 362 crore, with an EBITDA margin of 18.4%.

2. **Future Outlook and Growth Drivers:** Management aims for industry-leading growth through in-house innovation, M&A, and in-licensing, particularly focusing on dermatology and ophthalmology. Upcoming launches in these segments, including a portfolio for the domestic market and international filings for new products, are expected to drive growth.

3. **Order Book and Operational Updates:** The company has benefited from integrating the Mantra acquisition, achieving a 34% growth in Canada and a strong 40% rise in emerging markets. Notably, growth in the non-ARV segment is a primary driver. Future opportunities include approvals for Liposomal Amphotericin B.

4. **Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Analysts sought clarity on revenue projections and profitability drivers. Margins are expected to improve, targeting a recovery of 300-400 basis points over the next few years as new products are launched and synergies from acquisitions are realized.

- **Market Position and Competitive Landscape:** Discussion highlighted challenges in establishing market share, particularly in the cardiac segment post-Sanofi integration. Emcure’s historical leadership in women’s health and differentiated products underpins its competitive strategy.

- **Operational Challenges or Risks:** Supply chain and sales disruptions due to restructuring were noted, with confidence expressed in overcoming these challenges.

- **Capex and Capital Allocation:** Questions about debt and capital allocation emphasized a desire for a net cash position by FY26, contingent on cash flow generation.

- **Strategic Priorities and Long-Term Vision:** Focus areas include dermatology, ophthalmology, and significant investments in biologics, with expectations to outperform industry growth rates.

5. **Market or Regulatory Updates:** The company anticipates stable growth in European markets moving forward and reinforces its pursuit of differentiated products in emerging markets, which are showing strong growth trends.

6. **Strategic Focus Areas:** Emcure is emphasizing specialization in oncology, derma, and metabolic disorders, alongside increasing focus on productivity and operational efficiency across its product portfolio.

7. **Investor Insight:** With a solid financial performance and proactive growth strategies, Emcure appears well-positioned for future growth, particularly in dermatology and innovative therapies. A cautious approach is encouraged while monitoring operational integration as a key factor for success. The overall growth potential and strategic direction align favorably toward a positive investment outlook.